Impact of Comorbidity on Treatment Response to Paroxetine in Pediatric Obsessive-Compulsive Disorder: Is the Use of Exclusion Criteria Empirically Supported in Randomized Clinical Trials?

2003 ◽  
Vol 13 (supplement 1) ◽  
pp. 19-29 ◽  
Author(s):  
Daniel A. Geller ◽  
Joseph Biederman ◽  
S. Evelyn Stewart ◽  
Benjamin Mullin ◽  
Colleen Farrell ◽  
...  
1991 ◽  
Vol 1 (3) ◽  
pp. 277-279
Author(s):  
N.A Fineberg ◽  
T Bullock ◽  
D.B Montgomery ◽  
S.A Montgomery

Author(s):  
Golda S. Ginsburg ◽  
Julie Newman Kingery ◽  
Kelly L. Drake ◽  
Marco A. Grados

2002 ◽  
Vol 14 (3) ◽  
pp. 249-253 ◽  
Author(s):  
Robin A. Hurley ◽  
Sanjaya Saxena ◽  
Scott L. Rauch ◽  
Rudolf Hoehn-Saric ◽  
Katherine H. Taber

2018 ◽  
Vol 31 ◽  
pp. 150-151 ◽  
Author(s):  
Biju Viswanath ◽  
Reshma Jabeen Taj MJ ◽  
Ravi Kumar Nadella ◽  
Tulika Shukla ◽  
Madhuri H. Nanjundaswamy ◽  
...  

Author(s):  
Dan J. Stein

Anxiety disorders are the most prevalent of the mental disorders, and good translational models of these conditions encourage pharmacotherapy studies. This chapter discusses six randomized clinical trials that have contributed significantly to the pharmacotherapy of anxiety and related disorders, including generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, and social anxiety disorder. Although any such list is necessarily incomplete, these selections may shed light on early and ongoing challenges in the field and on key advances to date. After reviewing these foundational papers, the advances they represent, and the work that they have given impetus to, the chapter closes by considering future directions in work on the pharmacotherapy of anxiety and related disorders.


2005 ◽  
Vol 66 (12) ◽  
pp. 1549-1557 ◽  
Author(s):  
David F. Tolin ◽  
Jonathan S. Abramowitz ◽  
Gretchen J. Diefenbach

Sign in / Sign up

Export Citation Format

Share Document